Workflow
*ST目药(600671) - 2015 Q3 - 季度财报
TMSPTMSP(SH:600671)2015-10-27 16:00

Financial Performance - Operating revenue for the first nine months was CNY 68,288,950.37, a decline of 39.50% year-on-year[7] - Net profit attributable to shareholders was CNY -13,173,227.80, representing a decrease of 851.96% compared to the same period last year[7] - Basic earnings per share dropped to CNY -0.1029, a decline of 671.67% year-on-year[8] - Total operating revenue for the third quarter was ¥24,757,692.24, a decrease of 9.1% from ¥27,292,167.89 in the same period last year[24] - Net profit for the third quarter was a loss of ¥7,216,943.09, compared to a profit of ¥4,166,870.98 in the same period last year[25] - Year-to-date net profit (January to September) was a loss of ¥13,394,062.70, compared to a profit of ¥2,215,899.88 in the same period last year[25] - The company reported a total of CNY -487,260.93 in other operating income and expenses for the period[10] Cash Flow - The net cash flow from operating activities was CNY -12,349,093.56, worsening from CNY -4,474,331.33 in the previous year[7] - Cash inflow from operating activities totaled 73,434,628.60 RMB, down from 95,820,170.08 RMB year-on-year[32] - Cash outflow from operating activities was 85,783,722.16 RMB, compared to 100,294,501.41 RMB in the same period last year[32] - Cash flow from investing activities was -5,661,364.46 RMB, an improvement from -23,623,574.99 RMB year-on-year[33] - The ending cash and cash equivalents balance was 2,522,587.91 RMB, significantly lower than 23,709,092.50 RMB at the same time last year[33] Assets and Liabilities - Total assets decreased by 6.52% to CNY 267,020,178.70 compared to the end of the previous year[7] - The company's current assets totaled CNY 106,027,685.51, down from CNY 127,296,942.18 at the beginning of the year, indicating a decrease of about 16.7%[19] - The total liabilities decreased to CNY 195,165,959.36 from CNY 200,395,214.00, a reduction of about 2.5%[20] - The company's net loss for the period was CNY -130,696,264.08, compared to CNY -118,161,441.51 at the beginning of the year, indicating a worsening of approximately 10.5%[20] - The company’s inventory increased by 33.55% to CNY 64,287,258.37, driven by higher stock levels at the parent company and a subsidiary[13] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,604[11] - The largest shareholder, Caixin Fund, held 13.26% of the shares, totaling 16,143,825 shares[11] Expenses - Operating costs decreased by 30.49% to CNY 48,360,665.59 from CNY 69,570,525.95, reflecting the decline in sales volume[14] - The company reported a 63.92% reduction in selling expenses, amounting to CNY 7,537,650.41, attributed to decreased sales revenue[14] - The company reported a significant increase in management expenses, which rose to ¥20,361,901.78 for the first nine months, compared to ¥16,279,355.47 last year[24] Investment Activities - The company recorded an investment loss of ¥28,339,670.75, indicating challenges in its investment activities[28] Future Guidance - The company has not provided specific guidance for future performance or new product developments in the conference call[19] - The company has not yet submitted the non-public stock issuance proposal for shareholder approval as of the report date[15] Restructuring - The company is undergoing a major asset restructuring process, with due diligence and evaluations currently being conducted[15]